Genmab to begin pivotal front line CLL trial for ofatumumab
This article was originally published in Scrip
Executive Summary
Genmabwill begin new studies this year testing the experimental monoclonal antibody ofatumumab (HuMax-CD20) in chronic lymphocytic leukaemia (CLL) and follicular non-Hodgkin's lymphoma (NHL), including one pivotal trial in front line CLL which could pit it against Roche/Genentech's Rituxan (rituximab).